FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry, specifically a heterocyclic compound of formula (I), where each of W1 and W3 is independently N or CRc; W2 represents CRc; Z represents CN or 
; X represents H or (C1-C6)alkyl, where (C1-C6)alkyl is optionally substituted with 1 substituent independently selected from ORa; Y represents (C3-C6)cycloalkyl or (C6-C10)aryl, where (C6-C10)aryl is optionally substituted with 1 or 2 substituents independently selected from F; R1 represents Cl or ORa; Ra independently denotes H or (C1-C6)alkyl; and Rc is independently H. Also, the invention relates to the use of a compound of formula (I) and a pharmaceutical composition based on a compound of formula (I).
EFFECT: technical result: obtaining novel heterocyclic compounds useful in the treatment or prevention of a proliferative disorder.
14 cl, 7 tbl, 27 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROAROMATIC COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE MODULATORS | 2014 |
|
RU2672910C9 |
| SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | 2013 |
|
RU2650895C2 |
| INHIBITOR CONTAINING BICYCLIC DERIVATIVE, METHOD OF PREPARATION AND USE THEREOF | 2020 |
|
RU2820948C2 |
| HETEROCYCLIC COMPOUNDS AS TRK INHIBITORS | 2019 |
|
RU2803817C2 |
| DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS CONTAINING THEM, OBTAINING AND APPLICATION | 2004 |
|
RU2346938C2 |
| HETEROCYCLIC MAT2A INHIBITORS AND METHODS OF THEIR USE FOR CANCER TREATMENT | 2019 |
|
RU2809987C2 |
| MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | 2019 |
|
RU2778294C2 |
| MACROCYCLIC TYROSINE KINASE INHIBITOR AND ITS USE | 2019 |
|
RU2798231C2 |
| ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE DERIVATIVES OF AROMATICS, PHARMACEUTICAL COMPOSITION BASED ON THEM AND WAY OF TREATMENT AGAINST ABNORMALITIES RESPONSIVE TO DOPAMINE D RECEPTOR LIGAND TREATMENT, WITH THEIR HELP | 2005 |
|
RU2442781C2 |
| BROMDOMAIN INHIBITORS | 2012 |
|
RU2647592C2 |
